Pharmacokinetic Analysis of Nicotinamide Riboside

Aarhus University Hospital

Status and phase: Completed; Early Phase 1

Conditions: Healthy Participants

Treatments: Dietary Supplement: Nicotinamide riboside

Study type: Interventional

Funder types: Other

Identifiers

NCT02300740

45141

Details and patient eligibility

About

Nicotinamide riboside is a newly discovered vitamin B3. The pharmacokinetics in humans is so far not analyzed.

Enrollment: 12 patients

Sex: Male

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI 18-25, healthy, male,

Exclusion criteria

• liver or kidney diseases, other diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

12 participants in 2 patient groups

low dose

Experimental group

Description:

500 mg nicotinamide riboside oral

Treatment:

Dietary Supplement: Nicotinamide riboside

high dose

Experimental group

Description:

1000 mg nicotinamide riboside oral

Treatment:

Dietary Supplement: Nicotinamide riboside